Tetraphase Pharmaceuticals (TTPH) PT Raised to $13 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Tetraphase Pharma (TTPH) Prices 10M Shares at $6.50/Sh
July 28, 2017 5:57 AM EDTTetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share. The gross... More
Stifel Upgrades Tetraphase Pharmaceuticals (TTPH) to Buy, $15 PT
July 26, 2017 6:00 AM EDTStifel upgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Hold to Buy with a price target of $15.00 (from $8.00) following positive results from the second Phase 3 trial of the companys lead antibiotic, eravacycline, in complicated intra-abdominal infection (cIAI).
Analyst Stephen Willey said event serves as an... More
Tetraphase Pharma (TTPH) Reports Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections
July 25, 2017 4:29 PM EDTTetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive top-line results from IGNITE4, the Company's phase 3 clinical trial evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of patients with complicated intra-abdominal infections (cIAI). The results of IGNITE4, which enrolled 500 patients, demonstrated statistical non-inferiority of eravacycline to meropenem... More
